![Sonia Maria Poli](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sonia Maria Poli
Direktor/Vorstandsmitglied bei
DIMERIX LIMITED
Vermögen: 84 324 $ am 31.05.2026
Profil
Sonia Maria Poli is currently Independent Non-Executive Director at Dimerix Ltd. since 2015 and Managing Director & Director at Dimerix Bioscience Pty Ltd. since 2014.
Former roles include Global Head-Multidimensional Optimization at F.
Hoffmann-La Roche Ltd. in 2004, Chief Scientific Officer & Head-Development at Addex Therapeutics Ltd. from 2013 to 2017, Head-Translational Science at AC Immune SA from 2017 to 2019, Chief Scientific Officer at Minoryx Therapeutics SL from 2019 to 2020, and Chief Scientific Officer at Sibylla Biotech SpA from 2023 to 2024.
Education includes graduate and doctorate degrees from the University of Milan, conferred in 1990 and 1993 respectively.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DIMERIX LIMITED 0.11% | 12.12.2025 | 633’490 ( 0.11% ) | 84 324 $ | 31.05.2026 |
Aktive Positionen von Sonia Maria Poli
| Unternehmen | Position | Beginn |
|---|---|---|
| DIMERIX LIMITED | Direktor/Vorstandsmitglied | 03.07.2015 |
Dimerix Bioscience Pty Ltd.
 Dimerix Bioscience Pty Ltd. Pharmaceuticals: MajorHealth Technology Develops therapy for chronic kidney disease | Vorstandsvorsitzender | 01.05.2014 |
Ehemalige bekannte Positionen von Sonia Maria Poli
| Unternehmen | Position | Ende |
|---|---|---|
Sibylla Biotech Srl
 Sibylla Biotech Srl Internet Software/ServicesTechnology Services Operates drug discovery platform | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2024 |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Develops pharmaceutical products | Technik-/Wissenschafts-/F&E-Leiter | - |
| ADDEX THERAPEUTICS LTD | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2017 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01.01.2004 |
| AC IMMUNE SA | Corporate Officer/Principal | - |
Ausbildung von Sonia Maria Poli
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
71
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
AC Immune SA
 AC Immune SA Pharmaceuticals: MajorHealth Technology Manufactures precision medicines for neurodegenerative diseases | Health Technology |
Addex Therapeutics Ltd.
 Addex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs | Health Technology |
University of Milan
 University of Milan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dimerix Ltd.
 Dimerix Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research and development of biopharmaceutical drugs | Health Technology |
Dimerix Bioscience Pty Ltd.
Dimerix Bioscience Pty Ltd. Pharmaceuticals: MajorHealth Technology Develops therapy for chronic kidney disease | Health Technology |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Develops pharmaceutical products | Health Technology |
Sibylla Biotech Srl
Sibylla Biotech Srl Internet Software/ServicesTechnology Services Operates drug discovery platform | Technology Services |
